Citigroup
CRBU icon

Citigroup’s Caribou Biosciences CRBU Stock Holding History

Citigroup’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,900
Closed -$9.6K – 5855
2024
Q3 		$9.6K Buy
+4,900
New +$10K ﹤0.01% 5293

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup's CRBU Position: Q2 2026 in Review

Citigroup increased its Caribou Biosciences (CRBU) stake by 7.7% in Q2 2026, buying an estimated $8.67K and bringing the position to 61,311 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #4645.

Citigroup first reported a position in CRBU in Q3 2021 and has held it in 20 quarters since. The position peaked at $2.41M in Q1 2024. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Citigroup held 61,311 shares of Caribou Biosciences worth $108K as of Q2 2026.
  • Citigroup bought 4,388 Caribou Biosciences shares in Q2 2026, an estimated $8.67K.
  • Caribou Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4645 holding.
  • Citigroup first reported a position in Caribou Biosciences in Q3 2021 and has held it in 20 quarters since.
  • Citigroup's Caribou Biosciences position peaked at $2.41M in Q1 2024.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.